Comparison 5. RISPERIDONE DEPOT vs ORAL ARIPIPRAZOLE.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Global state: 1. Relapse (any reason)	1		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
1.1 long term	1	349	Risk Ratio (M‐H, Random, 95% CI)	1.05 [0.83, 1.33]
2 Global state: 3. Mean time in remission (days)	1		Mean Difference (IV, Random, 95% CI)	Subtotals only
2.1 long term	1	348	Mean Difference (IV, Random, 95% CI)	16.80 [‐43.59, 77.19]
3 Mental state: 1. Average change scores (PANSS, high score = worse)	1		Mean Difference (IV, Random, 95% CI)	Subtotals only
3.1 long term	1	349	Mean Difference (IV, Random, 95% CI)	‐0.10 [‐3.15, 2.95]
4 Leaving the study early: 1. Any reason	2	723	Risk Ratio (M‐H, Random, 95% CI)	0.83 [0.53, 1.30]
4.1 long term	2	723	Risk Ratio (M‐H, Random, 95% CI)	0.83 [0.53, 1.30]
5 Leaving the study early: 2. Specific	2		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
5.1 adverse events	2	723	Risk Ratio (M‐H, Random, 95% CI)	0.41 [0.05, 3.55]
5.2 insufficient response	1	349	Risk Ratio (M‐H, Random, 95% CI)	1.30 [0.29, 5.70]
5.3 withdrawn consent	2	723	Risk Ratio (M‐H, Random, 95% CI)	1.01 [0.67, 1.52]
5.4 due to relapse	1	374	Risk Ratio (M‐H, Random, 95% CI)	0.62 [0.36, 1.06]
5.5 loss to follow‐up	1	349	Risk Ratio (M‐H, Random, 95% CI)	1.75 [0.83, 3.68]
6 Adverse events: 1. General	2		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
6.1 any	2	729	Risk Ratio (M‐H, Random, 95% CI)	0.99 [0.87, 1.14]
6.2 serious	2	729	Risk Ratio (M‐H, Random, 95% CI)	0.96 [0.66, 1.39]
6.3 death	2	729	Risk Ratio (M‐H, Random, 95% CI)	0.98 [0.13, 7.36]
7 Adverse events: 2. Specific	2		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
7.1 anxiety	1	355	Risk Ratio (M‐H, Random, 95% CI)	1.21 [0.75, 1.94]
7.2 depression	1	355	Risk Ratio (M‐H, Random, 95% CI)	1.57 [0.85, 2.90]
7.3 psychosis	1	355	Risk Ratio (M‐H, Random, 95% CI)	1.04 [0.69, 1.56]
7.4 psychiatric symptoms	1	374	Risk Ratio (M‐H, Random, 95% CI)	0.81 [0.60, 1.09]
7.5 serious psychiatric symptoms	1	374	Risk Ratio (M‐H, Random, 95% CI)	0.75 [0.27, 2.08]
7.6 schizophrenia	1	355	Risk Ratio (M‐H, Random, 95% CI)	1.02 [0.63, 1.64]
7.7 prolactin related	2	729	Risk Ratio (M‐H, Random, 95% CI)	9.91 [2.78, 35.29]
7.8 hyperprolactinaemia	1	374	Risk Ratio (M‐H, Random, 95% CI)	12.13 [0.76, 193.65]
7.9 weight increase	1	374	Risk Ratio (M‐H, Random, 95% CI)	1.57 [0.38, 6.45]
7.10 nausea/vomiting	1	349	Risk Ratio (M‐H, Random, 95% CI)	1.25 [0.64, 2.43]
7.11 gastrointestinal	1	374	Risk Ratio (M‐H, Random, 95% CI)	0.27 [0.14, 0.55]
7.12 decreased appetite	1	355	Risk Ratio (M‐H, Random, 95% CI)	1.78 [1.00, 3.16]
7.13 diarrhoea	1	355	Risk Ratio (M‐H, Random, 95% CI)	0.62 [0.31, 1.24]
7.14 headache	2	729	Risk Ratio (M‐H, Random, 95% CI)	0.87 [0.46, 1.65]
7.15 insomnia	1	355	Risk Ratio (M‐H, Random, 95% CI)	0.91 [0.65, 1.27]
7.16 upper resp. tract infection	1	355	Risk Ratio (M‐H, Random, 95% CI)	0.38 [0.16, 0.89]
7.17 pyrexia	1	355	Risk Ratio (M‐H, Random, 95% CI)	1.16 [0.69, 1.97]
7.18 nasopharyngitis	1	355	Risk Ratio (M‐H, Random, 95% CI)	1.11 [0.58, 2.10]
7.19 dizziness	1	355	Risk Ratio (M‐H, Random, 95% CI)	1.89 [1.00, 3.58]
7.20 glucose related	1	355	Risk Ratio (M‐H, Random, 95% CI)	1.11 [0.58, 2.10]
8 Adverse events: 2. Specific 12. Mean (SD) weight increase in kg	1		Mean Difference (IV, Random, 95% CI)	Subtotals only
8.1 long term	1	355	Mean Difference (IV, Random, 95% CI)	1.0 [‐0.42, 2.42]
9 Adverse events: 3. Movement disorder	2		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
9.1 any extra pyramidal symptoms	2	729	Risk Ratio (M‐H, Random, 95% CI)	1.19 [0.91, 1.55]
9.2 tremor	1	355	Risk Ratio (M‐H, Random, 95% CI)	0.96 [0.65, 1.41]
9.3 akathisia	1	355	Risk Ratio (M‐H, Random, 95% CI)	0.98 [0.55, 1.76]